CSP 565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy VA NEPHRON-D Study.

Trial Profile

CSP 565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy VA NEPHRON-D Study.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 May 2015

At a glance

  • Drugs Lisinopril (Primary) ; Losartan (Primary)
  • Indications Diabetic nephropathies; Proteinuria
  • Focus Therapeutic Use
  • Acronyms VA-NEPHRON-D
  • Most Recent Events

    • 04 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 Aug 2011 Planned end date changed from 1 Jul 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
    • 26 Jun 2010 Design reported at 70th Annual Scientific Sessions of the American Diabetes Association; approximately 700 patients enrolled to date, mean age 65 years.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top